UNICYCIVE THERAPEUTICS, INC. Earnings Per Share (Basic)
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Earnings Per Share (Basic) of -$0.06 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.06.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.54, a 1450.00% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.68.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.33.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$1.67.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$5.65.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$1.28.
- UNICYCIVE THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$1.20.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.06 10-Q · filed 2026-08-12 | -$0.57 10-Q · filed 2026-08-12 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2026-03-31 | -$0.54 10-Q · filed 2026-05-12 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$1.59 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-12-31 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.67 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$0.33 10-Q · filed 2025-11-12 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.85 10-Q · filed 2025-11-12 | -$2.54 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-06-30 | -$0.52 10-Q · filed 2026-08-12 | -$0.49 10-Q · filed 2026-08-12 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.91 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-03-31 | $0.04 10-Q · filed 2026-05-12 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.53 derived: net income ÷ weighted average shares · filed 2026-05-12 | ||||
| 2024-12-31 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$2.63 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$2.91 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$5.65 10-K · filed 2026-03-30 | -$0.56 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$0.46 10-Q · filed 2025-11-12 | -$0.05 10-Q · filed 2024-11-13 | -$0.17 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$3.01 10-Q · filed 2025-11-12 | -$0.30 10-Q · filed 2024-11-13 | -$1.46 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-06-30 | $0.80 10-Q · filed 2025-08-14 | $0.08 10-Q · filed 2024-08-14 | -$3.35 10-Q · filed 2025-08-14 | -$0.34 10-Q · filed 2024-08-14 | -$1.06 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$1.14 derived: net income ÷ weighted average shares · filed 2025-08-14 | ||
| 2024-03-31 | -$0.61 10-Q · filed 2025-05-14 | -$0.83 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$0.98 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$1.29 derived: net income ÷ weighted average shares · filed 2025-05-14 | ||||
| 2023-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.36 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$1.28 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$0.13 10-Q · filed 2024-11-13 | -$0.37 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.12 10-Q · filed 2024-11-13 | -$1.48 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-06-30 | -$0.29 10-Q · filed 2024-08-14 | -$1.26 10-Q · filed 2024-08-14 | -$1.62 derived: net income ÷ weighted average shares · filed 2024-08-14 | -$1.99 derived: net income ÷ weighted average shares · filed 2024-08-14 | ||||
| 2023-03-31 | -$0.97 10-Q · filed 2024-05-13 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$1.70 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$1.94 derived: net income ÷ weighted average shares · filed 2024-05-13 | ||||
| 2022-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.72 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.96 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$1.20 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | -$0.37 10-Q · filed 2023-11-14 | -$0.61 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$0.85 10-Q · filed 2023-11-14 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2022-06-30 | -$0.24 10-Q · filed 2023-08-14 | -$0.48 10-Q · filed 2023-08-14 | -$0.66 derived: net income ÷ weighted average shares · filed 2023-08-14 | -$1.02 derived: net income ÷ weighted average shares · filed 2023-08-14 | ||||
| 2022-03-31 | -$0.24 10-Q · filed 2023-05-16 | -$0.42 derived: net income ÷ weighted average shares · filed 2023-05-16 | -$0.78 derived: net income ÷ weighted average shares · filed 2023-05-16 | |||||
| 2021-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.86 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | -$0.37 10-Q · filed 2022-11-14 | -$0.69 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.13 10-Q · filed 2022-08-15 | -$0.24 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | -$0.11 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | -$0.27 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |